UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15232, USA.
Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Nutrients. 2023 Jun 28;15(13):2930. doi: 10.3390/nu15132930.
There is an urgent need to identify biomarkers for advanced adenoma, an important precursor of colorectal cancer (CRC). We aimed to determine alterations in ileal juice bile acids associated with colorectal advanced adenoma.
We quantified a comprehensive panel of primary and secondary bile acids and their conjugates using an ultraperformance liquid chromatography triple-quadrupole mass spectrometric assay in ileal juice collected at colonoscopy from 46 study subjects (i.e., 14 biopsy-confirmed advanced adenomas and 32 controls free of adenoma or cancer). Using analysis of covariance (ANCOVA), we examined the differences in bile acid concentrations by disease status, adjusting for age, sex, body mass index, smoking status and type 2 diabetes.
The concentrations of hyodeoxycholic acid (HCA) species in ileal juice of the advanced adenoma patients (geometric mean = 4501.9 nM) were significantly higher than those of controls (geometric mean = 1292.3 nM, = 0.001). The relative abundance of ursodeoxycholic acid (UDCA) in total bile acids was significantly reduced in cases than controls (0.73% in cases vs. 1.33% in controls; = 0.046). No significant difference between cases and controls was observed for concentrations of total or specific primary bile acids (i.e., cholic acid (CA), chenodeoxycholic acid (CDCA) and their glycine- and taurine-conjugates) and total and specific major secondary bile acids (i.e., deoxycholic acid and lithocholic acid).
Colorectal advanced adenoma was associated with altered bile acids in ileal juice. The HCA species may promote the development of colorectal advanced adenoma, whereas gut microbiota responsible for the conversion of CDCA to UDCA may protect against it. Our findings have important implications for the use of bile acids as biomarkers in early detection of colorectal cancer.
迫切需要识别高级腺瘤的生物标志物,高级腺瘤是结直肠癌(CRC)的重要前体。我们旨在确定与结直肠高级腺瘤相关的回肠胆汁酸的变化。
我们使用超高效液相色谱三重四极杆质谱联用仪定量分析了回肠液中一组全面的初级和次级胆汁酸及其共轭物,该回肠液是从 46 名研究对象(即 14 名经活检证实的高级腺瘤和 32 名无腺瘤或癌症的对照)的结肠镜检查中收集的。我们使用协方差分析(ANCOVA),根据疾病状态调整年龄、性别、体重指数、吸烟状况和 2 型糖尿病来检查胆汁酸浓度的差异。
高级腺瘤患者(几何均数= 4501.9 nM)回肠液中 HCA 种的浓度明显高于对照组(几何均数= 1292.3 nM, = 0.001)。与对照组相比,总胆汁酸中的 UDCA 相对丰度明显降低(病例中为 0.73%,对照组中为 1.33%;= 0.046)。病例与对照组之间的总或特定初级胆汁酸(即 CA、CDCA 及其甘氨酸和牛磺酸共轭物)和总及特定主要次级胆汁酸(即 DCA 和石胆酸)的浓度没有显著差异。
结直肠高级腺瘤与回肠胆汁酸的变化有关。HCA 种可能促进结直肠高级腺瘤的发展,而负责将 CDCA 转化为 UDCA 的肠道微生物群可能会对此起到保护作用。我们的研究结果对使用胆汁酸作为结直肠癌早期检测的生物标志物具有重要意义。